BAYCOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Baycol, and what generic alternatives are available?
Baycol is a drug marketed by Bayer Pharms and is included in one NDA.
The generic ingredient in BAYCOL is cerivastatin sodium. Additional details are available on the cerivastatin sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BAYCOL?
- What are the global sales for BAYCOL?
- What is Average Wholesale Price for BAYCOL?
Summary for BAYCOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 37 |
| Patent Applications: | 2,698 |
| DailyMed Link: | BAYCOL at DailyMed |
US Patents and Regulatory Information for BAYCOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-001 | Jun 26, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-004 | Jun 26, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-002 | Jun 26, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-003 | Jun 26, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-006 | Jul 24, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAYCOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-002 | Jun 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-006 | Jul 24, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-001 | Jun 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-006 | Jul 24, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Pharms | BAYCOL | cerivastatin sodium | TABLET;ORAL | 020740-004 | Jun 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BAYCOL
See the table below for patents covering BAYCOL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 1123924 | ⤷ Sign Up | |
| Norway | 177005 | ⤷ Sign Up | |
| New Zealand | 227637 | SUBSTITUTED PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | ⤷ Sign Up |
| Hungary | 210727 | PROCESS FOR PRODUCING SUBSTITUTED PYRIDINE DERIVATIVES AND PHERMACEUTICAL COMPOSITION COMPRISING THEM AS ACTIVE SUBSTANCES | ⤷ Sign Up |
| South Africa | 8900429 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BAYCOL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0491226 | 98C0026 | Belgium | ⤷ Sign Up | PRODUCT NAME: CERIVASTATINE NATRIUM; NAT. REGISTRATION NO/DATE: 187 IS 304 F 3 19980302; FIRST REGISTRATION: GB PL 00010/0226 19970213 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
